RTP Mobile Logo
Oncology Grand Rounds Series: Chimeric Antigen Receptor T-Cell Therapy (Webinar Audio Proceedings) — an NCPD-Accredited Program for Nurses
Released June 2021

Proceedings from the last in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Jeremy Abramson, Caron Jacobson and Noopur Raje on cases from the practices of Ms Sonia Glennie, Alli McClanahan and Ms Elizabeth Zerante. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with hematologic cancers.

    LEARNING OBJECTIVES

    • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational products.
    • Consider the efficacy of approved and investigational CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
    • Evaluate recently presented data documenting the benefit of CAR T-cell therapy for relapsed/refractory chronic lymphocytic leukemia (CLL), and educate patients regarding the potential clinical role of this strategy.
    • Appreciate available data documenting the activity of CAR T-cell therapy directed against BCMA (the B-cell maturation antigen), and apply this knowledge to identify patients with multiple myeloma (MM) who may be appropriate for this approach as part of a clinical trial.
    • Recognize common adverse events associated with FDA-approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
    • Recall ongoing research evaluating CAR T-cell-based approaches for various B-cell lymphomas, CLL and MM, and counsel appropriate patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
    CREDIT DESIGNATION STATEMENT
    Audio Program: This educational activity for 2 contact hours is provided by RTP during the period of June 2021 through June 2022.

    This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.5 contact hours is provided by RTP during the period of June 2021 through June 2022.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSCART2021/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2021/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSCART2021/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2021/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSCART2021.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Jeremy Abramson, MD
    Director, Center for Lymphoma
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Juno Therapeutics, a Celgene Company, Kymera Therapeutics, MorphoSys; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc.

    Caron Jacobson, MD
    Assistant Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Kite, A Gilead Company, Lonza, Novartis, Precision BioSciences; Contracted Research: Kite, A Gilead Company, Pfizer Inc, Precision BioSciences.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, bluebird bio, Celgene Corporation.

    Oncology Nurse Practitioners

    Sonia Glennie, ARNP, MSN, OCN
    Swedish Cancer Institute Center for Blood Disorders
    Seattle, Washington

    Speakers Bureau: Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.

    Alli McClanahan, MSN, APRN, ANP-BC
    Nurse Practitioner
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Elizabeth Zerante, MS, AGACNP-BC
    APN Inpatient Hematopoietic Cellular Therapy Service
    University of Chicago Medicine
    Chicago, Illinois

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Bristol-Myers Squibb Company.

    Release date: June 2021
    Expiration date: June 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):